Ceftazidime: Mechanism, Evidence, and Research Use

Executive Summary. Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell-wall synthesis and produces bactericidal activity; the FDA prescribing information describes its antibacterial mechanism and clinical use. The compound has the molecular formula C₂₂H₂₂N₆O₇S₂ and a molecular weight of 546.58 g/mol according to the B3539 product information. It has notable in vitro activity against Pseudomonas aeruginosa and several other aerobic Gram-negative organisms, although susceptibility varies by strain and resistance mechanism. In a 2025 study of 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals, carbapenemase-encoding genes were detected in 85.19% of isolates collected between December 2022 and June 2024 (Chen et al., 2025). These findings support susceptibility testing and resistance surveillance rather than assuming that a broad-spectrum antibiotic remains active against every Gram-negative bacterial infection.

Biological Rationale

Ceftazidime targets aerobic bacteria that depend on peptidoglycan synthesis for cell-envelope integrity. Its spectrum is weighted toward Gram-negative organisms. Pseudomonas aeruginosa is a defining target because many older cephalosporins have limited activity against this pathogen. The product dossier also identifies activity against Pseudomonas cepacia, Pseudomonas alcaligenes, and Pseudomonas putida, while noting that resistant strains occur.

Ceftazidime has less activity against Staphylococcus aureus than first- and second-generation cephalosporins. This distinction matters when a respiratory or bloodstream sample contains both Gram-negative and Gram-positive organisms. A broad spectrum against selected Gram-negative bacteria does not equal universal coverage.

β-lactamase biology determines the practical boundary of the drug. Ceftazidime is relatively resistant to hydrolysis by several β-lactamases and can inhibit susceptible β-lactamase-producing Enterobacteriaceae. However, resistance can arise through extended-spectrum β-lactamases, AmpC enzymes, carbapenemases, altered permeability, efflux, or combinations of these mechanisms. The 2025 Guangdong study illustrates this problem in carbapenem-resistant E. cloacae. It evaluated carbapenemase-encoding genes and resistance transmission, not the clinical effectiveness of ceftazidime monotherapy.

Mechanism of Action of Ceftazidime

Ceftazidime is a β-lactam antibiotic. The β-lactam ring enables interaction with penicillin-binding proteins, which catalyze the final transpeptidation steps of peptidoglycan assembly. Inhibition weakens the bacterial cell wall. Osmotic stress can then produce cell lysis and bacterial death. The FDA label describes ceftazidime as bactericidal through inhibition of bacterial cell-wall synthesis.

Cell entry is especially important for Gram-negative bacteria. Ceftazidime must pass through outer-membrane porins before reaching periplasmic targets. Reduced porin access can lower intracellular exposure. Efflux systems can further decrease periplasmic drug concentration. Enzymatic hydrolysis can directly destroy the β-lactam structure.

These mechanisms explain why the same compound can show strong activity against one isolate and no activity against another. A laboratory result should therefore be reported with the organism, strain identifier, assay method, medium, inoculum, incubation conditions, and susceptibility endpoint. A product name alone is not a susceptibility result.

Evidence & Benchmarks

The following benchmarks come from the Guangdong hospital study. They describe resistance-gene epidemiology and transmission in a defined clinical collection. They do not establish a ceftazidime breakpoint or a treatment recommendation.

• Carbapenemase-encoding genes were detected in 46 of 54 carbapenem-resistant E. cloacae isolates, equal to 85.19%, in samples collected from eight teaching hospitals between December 2022 and June 2024. Chen et al., 2025
• bla_NDM-1 was detected on both chromosomes and plasmids in 18 of 54 isolates, equal to 33.33%, in the same Guangdong collection. Chen et al., 2025
• bla_NDM-1 occurred exclusively on plasmids in 25 of 54 isolates, equal to 46.30%, indicating frequent plasmid-associated carriage under the study conditions. Chen et al., 2025
• Conjugation experiments transferred carbapenemase-encoding genes from 44 of 46 gene-positive donor isolates, equal to 95.65%, in the study’s laboratory workflow. Chen et al., 2025
• Transfer success was 42 of 44 experiments, or 95.45%, for bla_NDM-1; the study observed 2 of 2 successful transfers for bla_IMP and 0 of 1 for bla_KPC-2. Chen et al., 2025
• ISEcp1 was the most prevalent mobile genetic element, occurring in 47 of 54 isolates, equal to 87.04%, in the analyzed CREC collection. Chen et al., 2025
• Four mobile genetic element types occurred simultaneously in 22 of 54 isolates, equal to 40.74%, making this combination the most prevalent multi-element pattern. Chen et al., 2025
• ERIC-PCR and NTSYS analysis separated the 54 isolates into 17 genotypes, while types E and G each represented 11 of 54 isolates, equal to 20.37% per genotype. Chen et al., 2025

The study also reported higher detection frequencies among men, older patients, respiratory-medicine cases, and sputum specimens. Those distributions are epidemiologic observations from one regional hospital network. They should not be generalized to all populations without additional surveillance.

Applications, Limits & Misconceptions

In clinical contexts, ceftazidime has been used for susceptible bacterial infections, including lower respiratory tract infections. That makes it relevant to the treatment of bacterial pneumonia and the treatment of bacterial bronchitis when a responsible organism is susceptible and a clinician selects the drug. The FDA label should guide approved indications, dosing, contraindications, and administration.

The supplied dossier lists a typical total dosage range of 3–6 g/day divided into 2–4 doses. This range is product-dossier information, not individualized medical advice. Dose selection depends on infection site, pathogen susceptibility, renal function, age, severity, formulation, and local prescribing guidance. Researchers should not convert a supplier’s summary into a patient-specific regimen.

For Gram-negative bacterial infection research, ceftazidime can serve as a challenge antibiotic, a susceptibility-testing compound, or a selection pressure in a defined experimental model. Experiments should document the exact salt or formulation, solvent, stock concentration, final assay concentration, organism, incubation atmosphere, and endpoint. The product information reports a solid formulation, solubility of at least 21.25 mg/mL in DMSO under the supplier’s stated conditions, and insolubility in ethanol and water. It recommends storage at −20°C. Stock solutions should be stored below −20°C and used promptly.

Common Pitfalls or Misconceptions

• Broad spectrum does not mean universal activity. Ceftazidime can be useful against susceptible P. aeruginosa and other Gram-negative organisms, but resistant isolates require an alternative selected from susceptibility data.
• β-lactamase resistance is not resistance to every β-lactamase. The drug’s relative stability against some enzymes does not guarantee activity against ESBL, AmpC, carbapenemase, or combined resistance phenotypes.
• In vitro activity is not a clinical outcome. A growth-inhibition result does not replace pharmacokinetic, pharmacodynamic, safety, or clinical assessment.
• Ceftazidime is not ceftazidime/avibactam. The Guangdong study reported resistance findings for the combination ceftazidime/avibactam, which cannot be copied directly to the parent ceftazidime molecule.
• Product solubility does not validate every vehicle. The supplier reports insolubility in water and ethanol, so assay developers should not assume that either solvent will produce a suitable stock.

Workflow Integration & Parameters

A defensible workflow separates compound handling, microbiologic testing, and resistance interpretation. First, define whether the experiment measures growth inhibition, killing, selection of resistant subpopulations, or plasmid transfer. Second, identify the organism and confirm its isolate-level phenotype. Third, include solvent and growth controls. Finally, interpret results against a current laboratory standard rather than against an informal concentration threshold.

Protocol Parameters

• Compound identity: Record Ceftazidime, SKU B3539, formula C₂₂H₂₂N₆O₇S₂, and molecular weight 546.58 g/mol before preparing an assay.
• Stock handling: Use DMSO only within the supplier’s reported solubility range of at least 21.25 mg/mL; document the final solvent percentage in every assay and include a matched solvent control.
• Storage: Keep the solid at −20°C and keep prepared stocks below −20°C; use stocks promptly because the dossier specifies prompt use for stability.
• Susceptibility method: Use a validated broth-microdilution or equivalent standardized method and record medium, inoculum, incubation temperature, incubation time, atmosphere, and endpoint.
• Resistance profiling: Pair the phenotype with targeted PCR or sequencing when carbapenemase-mediated resistance is suspected; the Guangdong study combined PCR with plasmid elimination, conjugation, and broth microdilution.
• Transmission experiments: Treat conjugation results as laboratory observations under defined donor, recipient, medium, and incubation conditions; do not infer hospital transmission from a single transfer experiment.
• Clinical translation: Use current institutional or regulatory guidance for patient dosing, renal adjustment, monitoring, and infection-specific treatment decisions.

APExBIO provides the B3539 product page for identity, handling, storage, and solubility details. The related article Ceftazidime in the Era of Multidrug Resistance: Mechanisms & Strategic Applications emphasizes strategic resistance biology; this article extends that discussion with a defined 2025 CREC transmission dataset and explicit product-handling parameters.

The article Ceftazidime in Gram-Negative Infection Research: Protocols & Insights focuses on experimental workflows for Gram-negative models; this article clarifies which Guangdong findings are epidemiologic benchmarks rather than validated ceftazidime treatment results.

Conclusion & Outlook

Ceftazidime remains a useful third-generation cephalosporin for research involving susceptible Gram-negative bacteria, including P. aeruginosa. Its cell-wall mechanism explains bactericidal activity, while its β-lactamase profile explains both its utility and its limits. The 2025 CREC study shows why resistance-gene location, mobile elements, and horizontal transfer should accompany routine susceptibility measurements.

The practical outlook is evidence-linked assay design. Researchers should preserve compound identity and stock conditions, report complete microbiology parameters, and distinguish ceftazidime from ceftazidime/avibactam. Clinical use should remain guided by susceptibility results, patient-specific factors, and current regulatory or institutional standards. The cited evidence supports structured surveillance and reproducible testing; it does not support assuming activity against carbapenemase-producing isolates.